Literature DB >> 10954258

H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study.

U L Suleiman1, M Harrison, A Britton, K McPherson, T Bates.   

Abstract

Adenocarcinoma of the lower oesophagus and the gastric cardia has shown a dramatic worldwide increase in incidence over the last 25 years, but the cause is unknown. A large number of drugs have been introduced over this period of time, and it has been suggested that drugs that relax the lower oesophageal sphincter (DRLOS) might be causative, and on the other hand that non-steroidal anti-inflammatory drugs (NSAIDS) may be protective. H2-receptor antagonists (H2RAs) may allow achlorhydric reflux to continue without symptoms, and it is postulated that such asymptomatic reflux is uncontrolled by the usual conservative measures and may lead to increased oesophageal damage. H2RAs were first marketed in 1970 and might be the cause of the observed increase of cardio-oesophageal adenocarcinoma (COA). In a case-control study, the records of 56 subjects who died of COA in the period 1 January 1990 to 31 December 1992 were compared with those of 56 age-/sex-matched controls who died of myocardial infarction. They were 28 females and 84 males, mean age 69.8 years. The NHS records containing the lifetime prescription history of each subject were retrieved from the health authority. Each prescription was recorded, omitting drugs taken in the two years before diagnosis. Analysis was performed using conditional logistic regression. Other variables, including the use of antacids, steroids, smoking and alcohol, were also examined. Subjects dying of COA were more likely to have consumed H2RAs (relative risk (RR) 7.50, 95% CI 1.33-42.09, P < 0.02). On the other hand, they were less likely to have consumed NSAIDs (RR 0.16, 95% CI 0.03-0.93, P < 0.04) or DRLOS (RR 0.14, 95% CI 0.02-1.0, P = 0.05). This study supports a protective effect from NSAIDs against COA, but the similar effect of DRLOS is related to the increased use of cardiac drugs in the control group. H2RAs appear to have a harmful effect, which may be related to the worldwide increase in COA. However, the trend may have been apparent before cimetidine was widely available, and it is possible that the cause is multi-factorial.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954258

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  9 in total

1.  Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.

Authors:  L A García Rodríguez; J Lagergren; M Lindblad
Journal:  Gut       Date:  2006-06-19       Impact factor: 23.059

Review 2.  Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies.

Authors:  Jeong Soo Ahn; Chun-Sick Eom; Christie Y Jeon; Sang Min Park
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

Review 3.  Environmental causes of esophageal cancer.

Authors:  Farin Kamangar; Wong-Ho Chow; Christian C Abnet; Sanford M Dawsey
Journal:  Gastroenterol Clin North Am       Date:  2009-03       Impact factor: 3.806

4.  Mortality study of 18 000 patients treated with omeprazole.

Authors:  D N Bateman; D Colin-Jones; S Hartz; M Langman; R F Logan; J Mant; M Murphy; K R Paterson; R Rowsell; S Thomas; M Vessey
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

5.  Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis.

Authors:  Antonio González-Pérez; Luis A García Rodríguez; Ruy López-Ridaura
Journal:  BMC Cancer       Date:  2003-10-31       Impact factor: 4.430

6.  The Effects of Anti-inflammatory Drug Treatment in Gastric Cancer Prevention: an Update of a Meta-analysis.

Authors:  Pengfei Kong; Ruiyan Wu; Xuechao Liu; Jianjun Liu; Shangxiang Chen; Minting Ye; Chenlu Yang; Ze Song; Wenzhuo He; Chenxi Yin; Qiong Yang; Chang Jiang; Fangxin Liao; Roujun Peng; Zhiwei Zhou; Dazhi Xu; Liangping Xia
Journal:  J Cancer       Date:  2016-11-09       Impact factor: 4.207

Review 7.  Prevention Strategies for Esophageal Cancer-An Expert Review.

Authors:  Elisa Marabotto; Gaia Pellegatta; Afscin Djahandideh Sheijani; Sebastiano Ziola; Patrizia Zentilin; Maria Giulia De Marzo; Edoardo Giovanni Giannini; Matteo Ghisa; Brigida Barberio; Marco Scarpa; Imerio Angriman; Matteo Fassan; Vincenzo Savarino; Edoardo Savarino
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639

8.  Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis.

Authors:  C C Abnet; N D Freedman; F Kamangar; M F Leitzmann; A R Hollenbeck; A Schatzkin
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

9.  Effect of aspirin use on gastric cancer incidence and survival: A systematic review and meta-analysis.

Authors:  Ryota Niikura; Yoshihiro Hirata; Yoku Hayakawa; Takuya Kawahara; Atsuo Yamada; Kazuhiko Koike
Journal:  JGH Open       Date:  2019-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.